AI CuratorAI-generated

Research summary · 7 d ago

AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

Pediatric-Onset MS Patients and CNS Specific Antibodies

A study involving 578 pediatric-onset MS patients revealed that CNS specific antibodies were more prevalent in those who tested positive for EBV EBNA-1 (92.2%) compared to matched controls (56.3%). Additionally, 56.6% of EBV EBNA-1 seronegative MS patients also exhibited high antibody levels, compared to 17.4% of seronegative controls.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42821346)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

These findings may suggest a potential link between EBV and CNS autoimmunity in pediatric MS, possibly indicating different pathways of disease risk depending on EBV status.

What this does not prove

This study does not establish causation between high levels of CNS autoreactive antibodies and the development of MS.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 578 · total of pediatric-onset MS patients studied
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-01
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceImpaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives. ↗DOI: 10.1073/pnas.2607529123

Supporting passages (7)

sample size578

sample size basisWe studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls.

publication date2026-10-01

comparatormatched controls

primary endpointCNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001).

findingsHowever, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls.

limitationsTitle: Impaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.